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What Is Chagas Disease?
American trypanosomiasis is a chronic
parasitosis caused by the kinetoplastid
parasite Trypanosoma cruzi and is highly
prevalent among a large variety of marsu-
pial and placental mammals autochtho-
nous to the American continent. The
infection is naturally transmitted by
blood-feeding Reduviid insects, but trans-
mission by oral contamination, transpla-
centally, or by blood transfusion or issue
transplantation is also common. The
human disease is known as ‘‘Chagas
disease’’ for the Brazilian physician who
described it over a century ago. The
human invasion of natural ecotopes as
well as the establishment of the vectors in
human dwellings associated with poor
socioeconomic conditions makes Chagas
disease a major public health hazard from
the United States to Argentina. As such,
the disease is a zoonosis that has afflicted
humanity since its earliest presence in the
New World and is still the largest parasitic
disease burden on the American continent
[1,2]. Recently, increased international
migrations have spread the infection to
nonendemic areas, including Western
Europe, Australia, and Japan, where
transmission is restricted to congenital
and transfusion or solid organ transplant.
In most infected individuals, a highly
effective immune response controls the
initial infection but fails to eradicate it.
The consequential lifelong infection and
associated inflammatory response result in
symptomatic cardiac and digestive disease,
significant morbidity, and eventually death
in 30%–40% of patients.
Successes and Advances
Among the successes in the control and
prevention of Chagas disease is the
reduction of vector-based transmission in
some countries in the Southern Cone of
South America using a combination of
widespread and recurrent domestic appli-
cation of pyrethroid insecticides and
screening of blood donations to prevent
transfusion-related transmission. Chagas
disease also benefits from having two
nitro-heterocyclic drugs (benznidazole
and nifurtimox) that have proven to be
partially effective in use for .40 years in
humans. The fact that T. cruzi infects
many different mammal species is both a
curse and blessing, as this parasite will
never be eradicated and thus there will
always be a risk of infection to humans.
However, the wide host range of T. cruzi
provides multiple excellent and highly
relevant host models to evaluate immune
responses and test specific treatments. This
latter advantage is rare among neglected
diseases. Furthermore, nonhuman host
species that serve as links in the transmis-
sion to humans are being identified and
can be targeted for control of transmission.
The imminent completion of clinical trials
to assess the benefit of treatment with
benznidazole during chronic infection in
humans should address a long-standing
question regarding the clinical benefit of
treating patients with long-established
chronic T. cruzi infections [3–5]. In
addition, human clinical trials of several
new therapies are advancing or have been
recently completed [5–7].
In addition to these operational advanc-
es, research developments over the last 20
or more years provide baseline informa-
tion for improving detection, prevention,
and control of T. cruzi infection. In
contrast to long-held views on the auto-
immune origin of the pathology of the
chronic stage of Chagas disease, multiple
lines of investigation confirm that the
persistence of parasites is the key factor
underlying the sustained inflammatory
responses that lead to such manifestations
[8,9]. Thus, the condition should be
treated as an infectious, not an autoim-
mune, disease, and specific treatment
should be offered to all seropositive
patients, perhaps with the exception of
those with terminal disease [2,10]. The
challenges for sensitive serodiagnosis of T.
cruzi infection and Chagas disease remain
to be solved. The use of multiple, partially
informative tests that ignore ‘‘discordant’’
samples (i.e., those positive on one but not
all serologic tests) is not a sustainable and
effective way to identify all those who need
treatment. The mechanisms of action of
existing treatments are only beginning to
be understood [2,11], and this provides
hope that we can ultimately understand
why treatment sometimes fails. Novel
treatment regimens and combination ther-
apies with currently available drugs, as
well as drug candidates with novel mech-
anisms of action, are being preclinically
[12–14] and clinically evaluated [5–7,15].
Studies of the immune response to T. cruzi
are identifying ways in which we may
enhance parasite-specific immune respons-
es [16] but are also raising questions about
the potential for developing effective
vaccines in the foreseeable future.
What Are the 2020 London
Declaration Goals for Chagas
Disease?
The London Declaration on Neg-
lected Tropical Diseases (http://www.
unitingtocombatntds.org/) is an effort to
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eliminate or control ten neglected diseases
by 2020—six years from now. Chagas
disease is among these. The effort was
launched in January 2012, spearheaded by
the WHO and the Bill and Melinda Gates
Foundation (BMGF) and including in the
collaboration many of the world’s leading
pharmaceutical companies. To set specific
goals and monitor achievement of those
goals, the principals behind the London
Declaration have established milestones
for each disease (Table 1) and plan a
yearly review and issuance of a ‘‘score-
card’’ of progress. For Chagas disease, the
initial milestones were established primar-
ily by WHO with rather limited input
from the research community, at-risk
communities, patient associations, or
healthcare services within endemic coun-
tries. The purpose of the present docu-
ment is to (1) assess these milestones and
address if they can be achieved and if so,
how; (2) propose additional milestones
when appropriate and document other
achievements to date towards these goals,
and (3) identify the tools, infrastructure, and
resources that are needed to achieve the
overall goal of effective control of T. cruzi
infection by the targeted 2020 date.
Additional input on the London Declara-
tion milestones (as well as a quick view of
the current scorecard) can also be logged at
https://sites.google.com/site/chagasddc/
home/chagas-disease-milestones.
Current Status of Chagas
Disease
1. The full magnitude of the problem is
only a guess because screening for
infection is inconsistently applied, es-
pecially in endemic, resource-con-
strained rural areas in which infection
prevalence has been historically high—
‘‘seek, and ye shall find.’’
2. Current diagnostics probably identify
the majority but certainly not all
infected individuals, even when the
standard two or three distinct testing
platforms are used.
3. Vector transmission of T. cruzi has
been interrupted only in some coun-
tries or regions of the Southern Cone.
The sustainability of that achievement
and its extension to other endemic
areas is compromised by, among other
factors, persisting infestations after
routine insecticide spraying, abun-
dance of other vector species, limited
resources, lack of sustained political
will, decentralization of disease control
programs, dwindling numbers of
trained personnel in charge of vector
control operations, and the ever-in-
creasing expansion of dengue out-
breaks [17–19]. Recent documentation
in northern Argentina and Bolivia of
increasing numbers of foci of vector
species highly resistant to the frontline
pyrethroids may make current vector
control protocols useless in some of the
regions of highest transmission [20–
22]. New and better insecticides are
not in the pipeline. Little is known
about the impact of the dramatic
changes in the demographic and eco-
logical landscape of Latin America on
the extent and modes of T. cruzi
transmission to humans. It is also
becoming increasingly clear that trans-
mission of T. cruzi is not limited to
rural communities; urban and periur-
ban vector-mediated transmission has
been documented in Peru, Bolivia,
Argentina, Mexico, and Venezuela,
among others [23,24].
4. Although reports of T. cruzi transmis-
sion unrelated to ‘‘conventional’’ vec-
tor infestation of houses, including via
contaminated food or drink, congenital
transmission, and by blood transfu-
sion and tissue transplantation,
have increased in recent decades
[25,26], and the extent and impact
of these transmission modes has not
been fully assessed in all affected
countries.
5. Although treatment of the infection
using currently available drugs can be
effective, this is not always the case
[2,27]. Treatment, when offered, is
generally restricted to only certain age
groups in urban settings, and it has
recently been estimated that less than
1% of those currently living with T.
cruzi infections have received treat-
ment [28]. Rural populations display
the highest levels of infection preva-
lence and the lowest treatment cover-
age rates—the quintessence of neglect
and inequity. The lack of screening
programs to identify those who are
infected and the inaccessibility of drugs
due to cost or inadequate supply
greatly limit the number of infected
individuals receiving treatment. How-
ever, perhaps the biggest bottleneck in
getting treatment to affected individu-
als is the lack of knowledge among at-
risk populations and health and health-
care personnel and thus a failure to
seek or prescribe treatment because of
lack of understanding of its benefits.
Many of these issues are surmountable
using resources and knowledge already
available—e.g., the capacity to pro-
duce affordable drugs is relatively high,
and adverse reactions to treatment can
be managed so that most can complete
treatment. Unfortunately, when treat-
ment failures occur, they are difficult to
detect due to the lack of validated
biomarkers for infection control or
parasitological cure [29–31].
Table 1. London Declaration: WHO proposed milestones for 2020.
100% screening of tranfusional transmission
100% of countries certified with no intradomiciliary transmission in Latin America
100% of countries certified with no vectorial domiciliary infestation in Southeast Asia and the Western Pacific
100% of countries with access to antiparasitic treatment
100% of countries with certification of organ transplantation interruption
100% of countries with certification of transfusional transmission interrupted
100% of countries with control of congenital transmission
100% of Latin American countries with a surveillance system and prevention measures for oral transmission
100% of infected/ill patients under care
Domiciliary transmission interrupted in the region of the Americas
doi:10.1371/journal.pntd.0003219.t001
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General Comments on the
Current London Declaration
Milestones for Chagas Disease
1. The wording of some of the milestones
makes it difficult to understand what is
being assessed and how. For example,
‘‘30% of countries with certification of
organ transplantation interruption’’
presumably indicates that effective
programs to prevent transmission of
infection via organ transplantation are
in place in 30% of countries.
2. Many terms are vague and require
more specific definition. For example,
what does being ‘‘certified’’ and having
‘‘certification’’ involve [32,33], and
what qualifies as ‘‘access to treatment’’
and ‘‘control of transmission?’’ What
specific countries make up the
‘‘100%?’’
3. Some milestones are addressing prob-
lems that are nonexistent, never exist-
ed, and are quite unlikely to emerge,
e.g., ‘‘countries certified with no vec-
torial domiciliary infestation on South-
east Asia and the Western Pacific.’’ A
more frequently cosmopolitan species,
Triatoma rubrofasciata, has been iden-
tified in Vietnam and other locations,
but no T. cruzi infection has been
demonstrated so far.
4. There are severe conflicts of interest in
setting the milestones and assessing
their achievement, with no indication
of how and by whom the achievement
will be determined and with what data.
The organizations leading the initiative
have a natural vested interest in
declaring, for example, that elimina-
tion of transmission has been achieved
in every county, department, state, or
country. The information used for
certifying the interruption of transmis-
sion is provided by the same health
authorities in charge of disease control
programs, who are also eager to claim
they have achieved elimination because
of the political value it affords. More-
over, current methods and procedures
used to assess transmission indices have
severe limitations [33]. The pressure to
claim success is enormous, and there is
very little expertise and independence
to actually determine that disease
transmission has been interrupted any-
where.
4. As a result, there is very little trust that
the certification of met milestones will
be believable or can endure the ‘‘curse
of success’’ and prevent disease resur-
gence in the foreseeable future. The
milestones also do not consider or
recommend the information systems
needed to be able to verify and validate
information. Where there is a persis-
tent problem, as in El Salvador, there is
no mention. Some control programs
have been shut down, as in Ecuador;
others have been downscaled, as in
Colombia; and disease control efforts
are passive and rudimentary in coun-
tries such as Mexico. Much of the data
in official documents have not been
independently verified to justify or back
up strategies, conclusions, and recom-
mendations.
5. Perhaps most importantly, the mile-
stones are based on the assumption
that the programs, tools, and resources
to achieve them are already in place.
They are not. Where are the diagnos-
tics, access to or a system for distribu-
tion of treatments, measurement of
vector infestation, and the integrated
bug control programs that are going to
be needed to achieve these milestones?
Expansion of treatment with benzni-
dazole is moving very, very slowly in
the most affected areas of the Southern
Cone countries and much less so
elsewhere, and it is not always a
question of drug availability but rather
lack of procurement procedures or
political priority and social equity.
Furthermore, the long-standing, wide-
spread foci of T. infestans highly
resistant to pyrethroids must be sup-
pressed immediately, their fate moni-
tored closely, and the results of these
efforts made public. More than a
decade after its discovery, there is no
further information regarding this
unique situation even though the
opportunity for spread of these resis-
tant vector populations is high.
6. Previous policy initiatives and docu-
mentation of successes in control or
elimination of transmission in the
regions are neither appropriately fo-
cused nor consistent with scientific
data. For example, there has been a
push to issue statements of elimination
of native triatomine species that thrive
in the wild and invade houses often,
some of them infected, but that only
occasionally transmit T. cruzi to hu-
mans [33]. Such initiatives allow dec-
larations of so called ‘‘success’’ but
have minimal impact on overall trans-
mission.
In short, by underestimating the mag-
nitude of the actual problem, overesti-
mating what has been achieved or is in
place and effective, and failing to
identify the actual challenges, the
London Declaration and Scorecard
continues to build the case that ‘‘we’re
moving fast and easily towards Chagas
elimination by the year 2020.’’ The
majority opinion in the scientific,
medical, and public health communi-
ties is that this is not the case. The
status of Chagas disease control is
highly heterogeneous between and
within regions and countries and even
within a given province, department,
or county.
What Needs to Be Done to
Reach the Goal of Control of
Chagas Disease by 2020?
1. Assess and carefully document the
current extent of the problem of
Chagas disease throughout the Amer-
icas.
a. Develop diagnostic tests that allow
for dependable and inexpensive
screening for all patient groups
and in all areas.
b. Implement screening programs
that will identify all infected indi-
viduals, regardless of age or other
demographic attributes, and estab-
lish comprehensive periodic (at
least annual) screening in areas
where transmission is possible or
likely.
c. Develop information systems to
inventory and track all screening,
treatment, and vector control ef-
forts at the local, state or province,
national, and international levels.
2. Reduce transmission.
a. Maintain and expand the vector
control infrastructure, manpower,
and expertise in all areas where
transmission is occurring. Provide
more training opportunities for
vector control personnel and
achieve high-quality application
of insecticides and rigorous evalu-
ation of their impact.
b. Design and implement sustainable
vector and transmission (including
oral, congenital, and transfusion or
transplantation) control programs
and develop independent assess-
ments to evaluate their efficacy.
c. Develop efficient and effective
monitoring systems to evaluate
vector interventions, including res-
ervoir community evaluation and
vector population dynamics.
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d. Identify the most common vehicles
for oral transmission (how com-
mon is oral infection in the
household setting, depending on
the endemic region?) and develop
methods to identify and prevent
such transmission (e.g., public
health education, facile methods
to test for contamination, etc.).
e. Institute uniform testing and treat-
ment of adolescents prior to child-
bearing years and women of repro-
ductive age, thus reducing oppor-
tunities for vertical transmission.
f. Facilitate commercialization of
high-quality assays for blood and
solid organ screening and educate
health care professionals to recog-
nize the need to screen solid organ
donors as potential sources of
infection.
g. Combine vector control efforts
with treatment and education pro-
grams to increase acceptability,
coverage, and sustainability.
3. Increase access to safe and effective
treatments.
a. Provide dependable and afford-
able access to supervised benzni-
dazole and nifurtimox treatment
in all endemic countries and re-
gions.
b. Promote the goal of promptly
diagnosing and treating all infected
individuals.
c. Use insights gained from ongoing
and completed clinical trials to
modify treatment paradigms.
d. Develop a better understanding of
how current treatments work and
when and why they fail and use
this information to improve treat-
ment regimens.
e. Discover and develop more effec-
tive treatments by pairing phar-
maceutical industry know-how
and resources with continuing
new understanding of parasite
biology and make use of in vitro
screening tools and rigorous in
vivo models for testing drug effi-
cacy. Evaluate drug combinations
in experimental and human Cha-
gas disease.
f. Develop the tools for accurate
assessment of treatment success in
humans. Patients and physicians
need to know if a particular
treatment has been effective. The
implementation of new treatment
regimens requires the ability to
accurately compare the efficacy of
treatment protocols in humans. At
present, this is not possible.
4. Establish accessible and rigorously
documented databases of diagnostic
screening efforts, vector control opera-
tions and programs, and treatment
programs so that progress towards the
London Declaration goals can be
effectively monitored and more easily
quantified.
5. Integrate Chagas disease into clinical
care systems in all countries using
workshops, courses, and continuing
education, and promote equal access
to diagnosis and clinical care.
Proposed Milestones for 2014–
2015
The milestones for the short term need
to focus on obtaining accurate informa-
tion, developing sound policies, and assur-
ing that insecticides, diagnostics, and drugs
are readily available.
1. Develop consensus policies for obtain-
ing reliable, representative surveys of
infected people (with and without
treatment), house infestation with tar-
get vector species, and coverage and
effectiveness of control efforts in all
affected countries.
2. Obtain commitments from health min-
istries from all endemic countries to
implement disease and vector control
policies that are developed in consul-
tation with the scientific community,
patient groups, and other nongovern-
mental organizations.
3. Investigate the means, including legis-
lation if needed, to implement routine
periodic diagnostic screening of all
primary school-age children and all
women of reproductive age living or
who have lived in areas where trans-
mission of T. cruzi is possible or likely.
4. Through input from scientists active in
drug development and testing and
clinicians with experience in treating
patients, develop a consensus docu-
ment on best practices for treating and
monitoring treatment outcomes for
those with T. cruzi infection.
5. Obtain an accurate assessment of
availability of benznidazole and nifur-
timox, including current commercial,
government and nongovernmental
stockpiles, country-by-country planned
distribution of those stores, anticipated
future needs, and the resources avail-
able and required to make treatment
readily available to all infected individ-
uals. Determine the country-by-coun-
try cost of treatment and the funds
available and/or needed to cover these
costs. Develop mechanisms to track
drug delivery and usage from the
federal stockpiles to the province, state,
and municipal levels.
6. Convene a meeting of researchers,
clinicians, industry representatives,
and nongovernmental organizations
to assess options for diagnosing T.
cruzi infection and to develop propos-
als to improve the quality and lower
the cost of screening and diagnostic
assays for T. cruzi infection.
7. Develop a reliable assessment of the
operational capacity of triatomine vec-
tor control programs (e.g., gear, vehi-
cles, personnel, and insecticides), pro-
gram strategies, where and how often
control operations are conducted, and
methods used to monitor their effec-
tiveness.
What Additional Advances Are
Needed by 2020 If Chagas
Disease Is to Be Eliminated as a
Human Health Problem?
Appropriate investments and political
commitment can translate into actions
that will reduce the impact of Chagas
disease significantly by 2020. As outlined
above, this will require a combination of
more efficient healthcare systems, infor-
mation systems, infrastructure (for diag-
nostic screening, vector control, drug
production and distribution, etc.), im-
proved tools (e.g., diagnostic assays, meth-
ods to monitor treatment efficacy, etc.),
and broader knowledge and a better
dialogue with communities and their
acceptance of and collaboration with these
projects. Without these developments, it is
virtually impossible that any of the pro-
posed 2020 milestones for Chagas disease
in the London Declaration can be met.
Establishing these milestones without a
plan to develop appropriate resources is a
recipe for failure.
In addition to the resources needed to
reduce the impact of Chagas disease by
2020 as described above, concurrently
there have to be additional investments
in research if Chagas disease is to be
eliminated as a human health problem,
including in the following areas:
1. Drug discovery and testing. There is
currently substantial interest and on-
going efforts in drug discovery for
Chagas disease. Unfortunately, many
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of these efforts are poorly organized,
disconnected, and woefully underfund-
ed. Drug discovery is often divorced
from parasite biology and pharmaco-
logical and infection parameters, prom-
ising leads are not vigorously pursued,
and existing drugs and clinical candi-
dates are not rigorously tested using the
best possible model systems. As a result,
compounds are going to clinical trials
with insufficient data—and then failing
in those trials—and the pipeline for
new clinical candidates is nearly empty.
Virtually nothing is known about the
mode of action of current drugs, and
efforts to optimize dosing strategies for
monotherapies and combination ther-
apies are nearly nonexistent. This is all
happening in a landscape of incredibly
good animal models for testing, includ-
ing many nonhuman primate species
with naturally acquired infections. T.
cruzi infection can be treated and
cured at any stage of the infection/
disease. It is inexcusable that more
people are not treated and that more
effective treatments are not being
effectively pursued.
2. Vector ecology and strategies for their
control. The insecticidal spraying of
houses to control vector species has
done more than any other method to
reduce the impact of Chagas disease.
However, a more integrated approach
is necessary for sustainable prevention.
There are a number of excellent
complementary interventions required
for transmission control (e.g., use of
insecticide-treated bednets or netting,
preventing bugs from feeding on ani-
mal reservoirs by use of insecticide-
treated dog collars, and/or vaccination
of potential reservoirs to reduce their
ability to transmit) [34,35]. Extensively
testing these methods individually or in
combination is likely to lead to im-
proved, lower cost and more sustain-
able vector control protocols. Invest-
ment in this area of research has to be
made if we expect to significantly and
permanently reduce the incidence of
human infection with T. cruzi.
3. Vaccine development. Prophylactic
vaccines are the most cost-effective
means to prevent many human infec-
tions. It is yet to be proven that T. cruzi
infection is vaccine preventable in any
host species. Nevertheless, efforts in this
area need to continue if for no other
reason than to determine if vaccines
are likely to be part of the long-term
strategy for prevention of T. cruzi
infection or if we will have to rely on
other transmission control tools and
treatment when these controls fail.
In addition to these research needs, it is
also essential to incorporate at-risk and
clinically affected populations into Chagas
disease public health and clinical care
program design and implementation. Civil
society should be an integral consultant or
collaborator in any public or private
initiative, and it is important to analyze
governance issues related to integration of
an effective Chagas disease program
within existing healthcare systems.
Final Thoughts
We believe that Chagas disease is a
solvable problem. The London Declaration
on Neglected Tropical Diseases initiative
provides an enormous opportunity to im-
plement solutions. This opportunity should
not be squandered by having weakly vetted
and ill-defined goals. We hope that the
current document can serve as a blueprint
that all the communities involved in and
affected by Chagas disease can contribute to
and rally around. We welcome comments
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